Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

NCT03935893 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Colorectal Cancer
Pancreatic Cancer
Sarcoma
Mesothelioma
Neuroendocrine Tumors
Squamous Cell Cancer
Merkel Cell Carcinoma
Mismatch Repair Deficiency
Microsatellite Instability

Interventions

BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)
DRUG: Fludarabine + Cyclophosphamide combination

Sponsor

Udai Kammula